Can red light improve vision? Some precisely defined eye-treatment protocols already have favourable clinical findings. However, these cannot be transferred to every laser, every eye condition or light applied through the nose. The delivery route, diagnosis and measured outcome must be distinguished. [2][3][4][5][6][7][8]
Full menu of the light research series — expand
Why does the retina need energy and oxygen?
Photoreceptors convert light into nerve signals, using energy in the process. Mitochondria produce ATP for cellular activity. PBM research examines how light absorption influences cellular respiration, signalling and responses to oxidative stress. Cytochrome c oxidase is among the mechanisms being investigated. [1]
The eye also needs an adequate blood supply. However, a biological link between energy and vessels does not by itself establish a treatment. A change in a blood measurement does not directly measure retinal oxygen supply or automatically mean sharper vision. Clinical outcomes require eye examinations. [1][4][7]
What did improved colour contrast mean?
In 2021, Shinhmar and colleagues studied ocular 670 nm application in healthy people aged approximately 37–70. In the main group of 20 participants, a single three-minute morning exposure was followed by average reductions of 17% and 12% in colour-contrast detection thresholds along two tested axes. Measurements were taken three hours later. [2]
In a subgroup of ten people, some improvement lasted a week; a small afternoon group did not show the same benefit. The study supports further investigation of application timing and visual ageing. It does not mean “17% sharper vision”, a cure for eye disease or proof that a nasal probe works. [2]
Dry macular degeneration: what is the clinical evidence?
Age-related macular degeneration, AMD, affects the retinal area needed for central vision. A pilot study by Merry and colleagues involving 42 eyes reported improved acuity and contrast sensitivity and reduced drusen volume after multiwavelength ocular PBM. Drusen are deposits beneath the retinal pigment epithelium; the study did not establish that better blood flow “washed them away”. [3]
LIGHTSITE III: a randomised controlled trial
The study enrolled 100 people and 148 eyes with dry AMD. The Valeda eye system used 590, 660 and 850 nm in repeated treatment cycles. A two-year analysis published in 2026 reported model-estimated mean gains of 6.2 letters in the active group and 2.4 letters in the control group at month 21. At month 24, the gains were 5.6 and 1.3 letters. [4]
Best-corrected visual acuity was measured on an ETDRS chart; five letters approximately equal one line. The between-group difference was statistically significant. An average does not guarantee the same result for every person. The manufacturer funded the research, and some participants did not complete the full follow-up. [4]
What does the FDA decision mean?
In 2024, the FDA authorised Valeda for a precisely defined group of patients with dry AMD. This concerns a specific eye system and indication in the United States. It does not authorise every form of red light, nasal applicator or use of light for vision. [5]
Do dry AMD findings also apply to diabetic eye damage?
In 2020, Shen and colleagues observed reduced macular swelling measured by OCT after ocular 670 nm application in a small open-label study of 21 patients. An open-label study cannot separate treatment effects from other influences as reliably as a well-designed controlled trial. [6]
The subsequent DRCR Retina Network study, Protocol AE, randomised 135 adults with diabetic macular oedema and good visual acuity. After four months, its 670 nm regimen showed no benefit over the control device in retinal thickness or visual acuity. [7]
Different diseases, stages and protocols can therefore produce different results. A positive finding in dry AMD is not evidence of effectiveness for every form of retinal damage. [4][7]
Could nasal application influence vision?
Intranasal application is being investigated for possible systemic responses, including blood properties and vascular regulation. Liu and colleagues studied lipids and rheological measurements with 650 nm light in 90 patients with vascular disease. They did not measure visual acuity, retinal status or intraocular pressure. [8]
An indirect influence on the eye’s supply therefore remains a hypothesis requiring specific testing. The nasal mucosa and retina are different target tissues. Light visible around the nose does not indicate the absorbed retinal dose, and the same wavelength does not imply the same eye effect. [1][8][10]
Is a nasal laser an established glaucoma treatment?
In the supplied manuscript, Ing. František Kokoš describes his own observation of elevated intraocular pressure decreasing after laser application, while values initially within the usual range remained within it. This is the author’s unpublished observation without a specified controlled protocol, not proof of effective glaucoma treatment.
Verification would require values in mmHg, the eye measured, timing, tonometer, application parameters, concurrent eye drops and repeated control measurements. A before-and-after comparison alone cannot establish the cause of a change. Intraocular pressure relates to aqueous humour production and drainage; it differs from blood pressure and retinal perfusion. [9]
Glaucoma damages the optic nerve and can develop even with pressure in the usual range. An ophthalmologist therefore sets the target pressure and treatment according to the overall findings. A lower reading on one occasion does not demonstrate nerve recovery. [9]
Does red light automatically mean eye-safe light?
Light dose depends on wavelength, power, area, time, pulsing and application site. More light does not necessarily mean more benefit. Device output energy is also not identical to the dose absorbed by the retina. [10]
A nasal applicator or ordinary light panel should not be redirected into the eye without an appropriate intended ocular use. Eye protocols use devices with specific safety requirements. Home experimentation does not replace examination or prescribed eye drops. [5][9][10]
Success is assessed according to the goal: acuity on an eye chart, the macula using OCT, and the optic nerve and visual field in glaucoma. Whether someone reads better and manages everyday activities also matters, rather than just a favourable-looking number. [4][7][9]
Frequently asked questions
What did improved colour contrast mean?
Participants could distinguish subtler colour differences. This is not the same as improving visual acuity by the same percentage or curing an eye condition. [2]
Dry macular degeneration: what is the clinical evidence?
LIGHTSITE III demonstrated a favourable visual acuity outcome with a specific ocular system in selected patients with dry AMD. The finding applies to the device, protocol and diagnosis studied. [3][4][5]
Could nasal application influence vision?
Nasal application has its own research on vascular and blood measures. However, the cited trial did not measure vision or eye pressure, so it cannot establish an improvement in eyesight. [8]
Does red light automatically mean eye-safe light?
No. The source, dose and intended use matter. Colour alone does not determine safety. [5][10]
Is a nasal laser an established glaucoma treatment?
The material discussed here does not support that conclusion. The author’s observation does not replace a controlled trial or prescribed treatment. [8][9]
Do dry AMD findings also apply to diabetic eye damage?
Not automatically. The controlled study in diabetic oedema with good acuity did not confirm a benefit from the tested regimen. [7]
Sources and research
Based on source material by Ing. František Kokoš. Updated 10 November 2026. Study findings apply to the specific conditions investigated.
- de Freitas LF, Hamblin MR. Proposed Mechanisms of Photobiomodulation or Low-Level Light Therapy. IEEE JSTQE. 2016;22:7000417. DOI: 10.1109/JSTQE.2016.2561201.
Open source ↗ - Shinhmar H et al. Weeklong improved colour contrasts sensitivity after single 670 nm exposures associated with enhanced mitochondrial function. Scientific Reports. 2021;11:22872. DOI: 10.1038/s41598-021-02311-1.
Open source ↗ - Merry GF et al. Photobiomodulation reduces drusen volume and improves visual acuity and contrast sensitivity in dry age-related macular degeneration. Acta Ophthalmol. 2017;95:e270–e277. DOI: 10.1111/aos.13354.
Open source ↗ - Jaffe GJ et al. Long-term efficacy and safety of photobiomodulation in dry age-related macular degeneration (LIGHTSITE III: 24-month analysis). Retina. 2026;46:783–795. DOI: 10.1097/IAE.0000000000004822.
Open source ↗ - FDA. Valeda Light Delivery System. De Novo classification review DEN230083. 2024.
Open source ↗ - Shen W et al. Preclinical and clinical studies of photobiomodulation therapy for macular oedema. Diabetologia. 2020. DOI: 10.1007/s00125-020-05189-2.
Open source ↗ - Kim JE et al.; DRCR Retina Network. A Randomized Trial of Photobiomodulation Therapy for Center-Involved Diabetic Macular Edema with Good Visual Acuity (Protocol AE). Ophthalmol Retina. 2022;6:298–307. DOI: 10.1016/j.oret.2021.10.003.
Open source ↗ - Liu TCY et al. Randomized, Double-Blind, and Placebo-Controlled Clinic Report of Intranasal Low-Intensity Laser Therapy on Vascular Diseases. Int J Photoenergy. 2012:489713. DOI: 10.1155/2012/489713.
Open source ↗ - National Eye Institute. Glaucoma and Eye Pressure.
Open source ↗ - Zein R, Selting W, Hamblin MR. Review of light parameters and photobiomodulation efficacy: dive into complexity. J Biomed Opt. 2018;23:120901. DOI: 10.1117/1.JBO.23.12.120901.
Open source ↗











